genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2011
Kidney cancer
Insights
Reporting from J.P. Morgan on Drug Development Companies
Cancer
Pfizer Scores New Approval for Sutent in Europe
Cancer
Pfizer’s Phase III Trial in mRCC Turns Up Positive Results
Cancer
Pfizer, AstraZeneca, and Actelion Separately Report Phase III Trial Failures
Cancer
Immatics Raises Nearly €54M to Take Lead Therapeutic Cancer Vaccine into Phase III
Cancer
GSK Taps NCCN to Conduct Cancer Clinical Testing for $4M
Cancer
Phase III Data Shows Novartis’ Afinitor More Than Doubles PFS in Pancreatic NET Patients
Best of the Web
What Are Electron Microscopes?
Cancer
Pfizer Quashes Three More Phase III Cancer Trials
Cancer
Roche’s Avastin Fails to Improve Survival of Advanced Stomach Cancer Patients in Phase III Trial
1
...
6
7
8
9
Page 7 of 9
Scroll Up